In the past 4 years, our increased understanding of prostate cancer biology and mechanisms of tumor resistance have led to a number of clinical trials using new therapeutic agents, resulting in several new FDA approvals. Additionally, new agents are currently under clinical investigation in continuous efforts to improve the efficacy and safety of Castration-Resistant Prostate Cancer (CRPC) treatment. The introduction of these novel therapeutic agents, however, requires physicians to make complicated decisions regarding treatment protocols for their patients with CRPC. Questions of agent selection, treatment sequencing methods, combination treatment strategies, and individualized therapeutic approaches for newly approved and emerging CRPC drugs remain unanswered. This activity aims to address these challenges through an interactive online opinion leader workshop with 3 experts in the field of prostate cancer discussing the clinical data regarding available and investigational agents and the most effective ways to utilize those agents for long-term disease control.